A clinical trial at the University of Alabama will be enrolling patients in the first-ever study of an open-label placebo in cancer.
A clinical trial at the University of Alabama will be enrolling patients in the first study of an open-label placebo in cancer. Cancer survivors with moderate-levels of cancer-related fatigue, who have completed treatments for at least 6 months, would be eligible to participate.
One group of participants will receive the placebo pill for 2 weeks and the second group will act as a control. The cohorts will trade places after a week-long washout period. Saliva samples from trial participants will be analyzed for potential biomarkers to identify genetic predisposition to a placebo response, if any.
The Program in Placebo Studies and the Therapeutic Encounter at Harvard University and Beth Israel Deaconess Medical Center, run by Ted Kaptchuk, has done several open-label placebo studies in patients with irritable bowel syndrome, migraine, and depression.
Read more at newswise: http://bit.ly/1Lo2wZ4
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More